SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National Medical Products Administration (NMPA) in China has accepted its Investigational New Drug (IND) filing for suciraslimab for review. The company anticipates initiating a Phase I clinical study for the drug in the treatment of early symptomatic Alzheimer’s disease (AD), encompassing mild cognitive impairment or dementia attributable to the disease.
Clinical Study and Suciraslimab’s Potential
The upcoming clinical study will focus on the efficacy and safety of suciraslimab in patients with AD. Suciraslimab is a CD22 monoclonal antibody (mAb) under development for the treatment of a range of conditions, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), non-Hodgkin’s lymphoma (NHL), Sjogren’s syndrome (SS), and Alzheimer’s disease. The drug’s dual mechanism of action involves binding to CD22, which promotes the clearance of β-Amyloid protein deposition and inhibits neuroinflammation, thereby alleviating Alzheimer’s symptoms and reducing adverse reactions such as brain edema and cerebral hemorrhage caused by amyloid protein-related imaging abnormalities (ARIA).
Regulatory Progress and Phase III Extension Study
Suciraslimab is currently undergoing a Phase III extension study in RA in China, and the company is awaiting regulatory decisions for this indication. The acceptance of the IND filing for AD is a significant step forward in the drug’s development and highlights SinoMab BioScience’s commitment to addressing unmet medical needs in neurodegenerative diseases.- Flcube.com
